{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:29:10Z","timestamp":1786696150470,"version":"build-2736575974"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Monogenic diabetes covers single-variant inherited subtypes of diabetes, of which the most prevalent are HNF4A-MODY (MODY1), GCK-MODY (MODY2), HNF1A-MODY (MODY3), HNF1B-MODY (MODY5) and mitochondrial diabetes. Together, they account for about 1% of diabetes cases, but more than 70% of affected individuals are classified with other forms of diabetes. The classical phenotype is young-onset, non-autoimmune diabetes with partially preserved insulin secretion and a family history of diabetes. Correct genetic diagnosis is crucial for family counselling and optimal diabetes management, as reviewed in this article.<\/jats:p>","DOI":"10.61409\/v10250809","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:25:12Z","timestamp":1782973512000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Monogenic diabetes"],"prefix":"10.61409","author":[{"given":"Mathilde","family":"Svendstrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne Skov","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Cathrine Baun","family":"Thuesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Maagensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"St\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Pang L, Colclough KC, Shepherd MH, et al. Improvements in awareness and testing have led to a threefold increase over 10 years in the identification of monogenic diabetes in the UK. Diabetes Care. 2022;45:642-649. https:\/\/doi.org\/10.2337\/dc21-2056","DOI":"10.2337\/dc21-2056"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Colclough K, Ellard S, Hattersley A, Patel K. Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of maturity-onset diabetes of the young. Diabetes. 2022;71:530-537. https:\/\/doi.org\/10.2337\/db21-0517","DOI":"10.2337\/db21-0517"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Patel KA, Ozbek MN, Yildiz M, et al. Systematic genetic testing for recessively inherited monogenic diabetes: a cross-sectional study in paediatric diabetes clinics. Diabetologia. 2022;65(2):336-342. https:\/\/doi.org\/10.1007\/s00125-021-05597-y","DOI":"10.1007\/s00125-021-05597-y"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Thuesen ACB, Backe MB, Garcia-Erill G, et al. High prevalence and common forms of maturity-onset diabetes of the young in Greenland. Can J Diabetes. 2025;49(3):142-151.e2. https:\/\/doi.org\/10.1016\/j.jcjd.2025.01.002","DOI":"10.1016\/j.jcjd.2025.01.002"},{"key":"ref4","unstructured":"St\u00f8y J, Johannesen H, Maagensen H, et al. National behandlingsvejledning: Monogenetisk diabetes, 2024. Endocrinology.dk. https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/monogenetisk-diabetes\/ (19. Feb 2026)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Sharp LN, Colclough K, Leech JM, et al. Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY. J Clin Endocrinol Metab. 2025:dgaf599. https:\/\/doi.org\/10.1210\/clinem\/dgaf599","DOI":"10.1210\/clinem\/dgaf599"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Chanoine JP, Thompson DM, Lehman A. Diabetes associated with maternally inherited diabetes and deafness (MIDD): from pathogenic variant to phenotype. Diabetes. 2025;74(2):153-163. https:\/\/doi.org\/10.2337\/db24-0515","DOI":"10.2337\/db24-0515"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Murray Leech J, Beaumont RN, Arni AM, et al. Common genetic variants modify disease risk and clinical presentation in monogenic diabetes. Nat Metab. 2025;7(9):1819-1829. https:\/\/doi.org\/10.1038\/s42255-025-01372-0","DOI":"10.1038\/s42255-025-01372-0"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kleinberger JW, Copeland KC, Gandica RG, et al. Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med. 2018;20(6):583-590. https:\/\/doi.org\/10.1038\/gim.2017.150","DOI":"10.1038\/gim.2017.150"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bonnefond A, Boissel M, Bolze A, et al. Pathogenic variants in actionable MODY genes are associated with type 2 diabetes. Nat Metab. 2020;2(10):1126-1134. https:\/\/doi.org\/10.1038\/s42255-020-00294-3","DOI":"10.1038\/s42255-020-00294-3"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41(4):467-473. https:\/\/doi.org\/10.1007\/s001250050931","DOI":"10.1007\/s001250050931"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Naylor RN, Patel KA, Kettunen JLT, et al. Precision treatment of beta-cell monogenic diabetes: a systematic review. Commun Med. 2024;4(1):145. https:\/\/doi.org\/10.1038\/s43856-024-00556-1","DOI":"10.1038\/s43856-024-00556-1"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Gambella A, Kalantari S, Cadamuro M, et al. The landscape of HNF1B deficiency: a syndrome not yet fully explored. Cells. 2023;12(2):307. https:\/\/doi.org\/10.3390\/cells12020307","DOI":"10.3390\/cells12020307"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Varughese R, Rahman S. Endocrine dysfunction in primary mitochondrial diseases. Endocr Rev. 2025;46(3):376-396. https:\/\/doi.org\/10.1210\/endrev\/bnaf002","DOI":"10.1210\/endrev\/bnaf002"},{"key":"ref14","unstructured":"Exter diabetes. Exeter Diabetes App. MODY probability calculator. https:\/\/www.diabetesgenes.org\/exeter-diabetes-app\/ModyCalculator (19. feb 2026)"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Kind L, Molnes J, Tjora E, et al. Molecular mechanism of HNF-1A-mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes. JCI Insight. 2024;9(11):e175278. https:\/\/doi.org\/10.1172\/jci.insight.175278","DOI":"10.1172\/jci.insight.175278"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27-42. https:\/\/doi.org\/10.1007\/s00018-008-8322-9","DOI":"10.1007\/s00018-008-8322-9"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Shepherd M, Pearson ER, Houghton J, et al. No deterioration in glycemic control in HNF-1\u03b1 maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care. 2003;26(11):3191-3192. https:\/\/doi.org\/10.2337\/diacare.26.11.3191-a","DOI":"10.2337\/diacare.26.11.3191-a"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Christensen AS, H\u00e6dersdal S, St\u00f8y J, et al. Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA). Diabetes Care. 2020;43(9):2025-2033. https:\/\/doi.org\/10.2337\/dc20-0408","DOI":"10.2337\/dc20-0408"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"\u00d8stoft SH, Bagger JI, Hansen T, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37(7):1797-1805. https:\/\/doi.org\/10.2337\/dc13-3007","DOI":"10.2337\/dc13-3007"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Maagensen H, H\u00e6dersdal S, Krogh J, et al. Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3). Diabet Med. 2024;(10)41:e15387. https:\/\/doi.org\/10.1111\/dme.15387","DOI":"10.1111\/dme.15387"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Maagensen H, H\u00f8yerup SO, Jensen JS, et al. Empagliflozin in HNF1A-MODY (MODY3): a randomised, double-blind, placebo-controlled, crossover trial. Diabetes Care. 2026; 12:dc252572. https:\/\/doi.org\/10.2337\/dc25-2572","DOI":"10.2337\/dc25-2572"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279-286. https:\/\/doi.org\/10.1001\/jama.2013.283980","DOI":"10.1001\/jama.2013.283980"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57(1):54-56. https:\/\/doi.org\/10.1007\/s00125-013-3075-x","DOI":"10.1007\/s00125-013-3075-x"},{"key":"ref24","unstructured":"Kauffmann A, J\u00f8rgensen IL, Thuesen AC, et al. Maturity-onset diabetes of the young og graviditet. Ugeskr Laeger. 2023;185:V02230067. https:\/\/ugeskriftet.dk\/videnskab\/maturity-onset-diabetes-young-og-graviditet"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yeung RO, Al Jundi M, Gubbi S, et al. Management of mitochondrial diabetes in the era of novel therapies. J Diabetes Complications. 2021;35(1):107584. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107584","DOI":"10.1016\/j.jdiacomp.2020.107584"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ishibashi R, Hirayama K, Watanabe S, et al. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes. J Diabetes Investig. 2023;14(12):1419-1422. https:\/\/doi.org\/10.1111\/jdi.14085","DOI":"10.1111\/jdi.14085"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"de Andrade PBM, Rubi B, Frigerio F, et al. Diabetes-associated mitochondrial DNA mutation A3243G impairs cellular metabolic pathways necessary for beta cell function. Diabetologia. 2006;49(8):1816-1826. https:\/\/doi.org\/10.1007\/s00125-006-0301-9","DOI":"10.1007\/s00125-006-0301-9"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med. 2001;134(9 Pt 1):721-728. https:\/\/doi.org\/10.7326\/0003-4819-134-9_Part_1-200105010-00008","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00008"},{"key":"ref29","unstructured":"MODERN-MODY. MODERN MODY - Optimal behandling af personer med s\u00e6rligt arvelig diabetes. https:\/\/www.sdcc.dk\/modern-mody\/Sider\/default.aspx\/ (19.02.26)"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:54:54Z","timestamp":1786694094000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V10250809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v10250809","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}